Tibolone and the Risk of Arterial Disease

1. Schwartz J Freeman R Frishman W. Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women. J Clin Pharmacol 1995; 35: 1–16.

2. Nasr A Breckwoldt M. Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg. Gynecol Endocrinol 1998; 12: 43–59.

3. Stampfer MJ Colditz CA . Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 1991; 20: 47–63.

4. Crook D. Effects of estrogens and progestogens on plasma lipids. Fraser IF Jansen RPS Lobo RA Whitehead MI (eds). In: Estrogens and Progestins in Clinical Practice 1998 pp 787–798, Churchill Livingstone, London, UK

5. Hulley S Grady D Bush T . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–613.

6. Rymer J. The effects of tibolone. Gynecol Endocrinol 1998; 12: 213–220.

7. Zandberg P Peters JLM Demacker PNM . Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arteriosclerosis Thromb Vasc Biol 1998; 18: 1844–1854.